Connect with us

Uncategorized

$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 – Featuring Amgen, Biocon, Dr. Reddy’s Laboratories and Intas Pharmaceuticals Among Others

$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 – Featuring Amgen, Biocon, Dr. Reddy’s Laboratories and Intas Pharmaceuticals Among Others
PR Newswire
DUBLIN, Jan. 21, 2023

DUBLIN, Jan. 21, 2023 /PRNewswire/ — Research and Markets
Th…

Published

1 year ago

on

$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 - Featuring Amgen, Biocon, Dr. Reddy's Laboratories and Intas Pharmaceuticals Among Others

PR Newswire

DUBLIN, Jan. 21, 2023

DUBLIN, Jan. 21, 2023 /PRNewswire/ -- Research and Markets

The "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.


The global erythropoietin drugs market size reached US$ 9.8 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 13.8 Billion by 2027, exhibiting a CAGR of 5.87% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Erythropoietin (EPO) is a hormone produced by kidneys to stimulate the production of red blood cells (RBCs). Its deficiency can lead to low hemoglobin levels and various medical conditions.

As a result, there is a rise in the demand for EPO drugs, also known as EPO stimulating agents (ESAs), which are produced synthetically using recombinant deoxyribonucleic acid (DNA) technology. They are usually administered via the intramuscular route and released into the bloodstream to stimulate RBC production.

At present, they are available in various types with different dosage schedules and modes of delivery. EPO drugs are generally given to patients undergoing chemotherapy, chronic renal failure, and antiviral drug therapy or at high risk for perioperative blood loss from surgical procedures.

Individuals who have anemia due to cancer, prematurity, and chronic kidney disease (CKD) are usually at the risk of low hemoglobin levels. This represents one of the key factors positively influencing the sales of EPO drugs worldwide. In addition, they are used to treat zidovudine among patients with human immunodeficiency virus (HIV) infection.

Moreover, the rising need for surgical interventions on account of the growing aging population across the globe is catalyzing the use of EOP drugs to minimize allogeneic blood transfusions after surgical procedures. Furthermore, the escalating demand for minimally invasive (MI) procedures is bolstering the growth of the market.

Apart from this, the increasing use of EPO drugs as a novel therapeutic agent in research settings is projected to expand their applications in treating various diseases. These diseases generally include spinal cord injury (SCI), depression, diabetes, acute kidney injury (AKI), recombinant therapy for patients with heart failure, and a neuroprotective agent in ischemic stroke.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global erythropoietin drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global erythropoietin drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global erythropoietin drugs market and who are the key players?
  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Erythropoietin Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class
6.1 Biologics
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Biosimilars
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Product Type
7.1 Epoetin-alfa
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Epoetin-beta
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Darbepoetin-alfa
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast

8 Market Breakup by Application
8.1 Hematology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Kidney Disorder
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cancer
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast

9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Homecare
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Specialty Clinics
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Amgen Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Biocon Limited
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Dr. Reddy's Laboratories Ltd.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche AG
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.5 Intas Pharmaceuticals Ltd.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 LG Chem Ltd.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Sun Pharmaceutical Industries Limited
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Teva Pharmaceutical Industries Ltd.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/60h6hx

Media Contact:

Laura Wood | +353-1-481-1716 | press@researchandmarkets.net

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/12-8-billion-worldwide-erythropoietin-drugs-industry-to-2027---featuring-amgen-biocon-dr-reddys-laboratories-and-intas-pharmaceuticals-among-others-301727160.html

SOURCE Research and Markets

Read More

Related Topics:
Continue Reading

Uncategorized

Another airline is making lounge fees more expensive

Qantas Airways is increasing the price of accessing its network of lounges by as much as 17%.

Published

1 hour ago

on

March 19, 2024

By

Over the last two years, multiple airlines have dealt with crowding in their lounges. While they are designed as a luxury experience for a small subset of travelers, high numbers of people taking a trip post-pandemic as well as the different ways they are able to gain access through status or certain credit cards made it difficult for some airlines to keep up with keeping foods stocked, common areas clean and having enough staff to serve bar drinks at the rate that customers expect them.

In the fall of 2023, Delta Air Lines  (DAL)  caught serious traveler outcry after announcing that it was cracking down on crowding by raising how much one needs to spend for lounge access and limiting the number of times one can enter those lounges.

Related: Competitors pushed Delta to backtrack on its lounge and loyalty program changes

Some airlines saw the outcry with Delta as their chance to reassure customers that they would not raise their fees while others waited for the storm to pass to quietly implement their own increases.

A photograph captures a Qantas Airways lounge in Sydney, Australia.

Shutterstock

This is how much more you'll have to pay for Qantas lounge access

Australia's flagship carrier Qantas Airways  (QUBSF)  is the latest airline to announce that it would raise the cost accessing the 24 lounges across the country as well as the 600 international lounges available at airports across the world through partner airlines.

More Travel:

Unlike other airlines which grant access primarily after reaching frequent flyer status, Qantas also sells it through a membership — starting from April 18, 2024, prices will rise from $600 Australian dollars ($392 USD)  to $699 AUD ($456 USD) for one year, $1,100 ($718 USD) to $1,299 ($848 USD) for two years and $2,000 AUD ($1,304) to lock in the rate for four years.

Those signing up for lounge access for the first time also currently pay a joining fee of $99 AUD ($65 USD) that will rise to $129 AUD ($85 USD).

The airline also allows customers to purchase their membership with Qantas Points they collect through frequent travel; the membership fees are also being raised by the equivalent amount in points in what adds up to as much as 17% — from 308,000 to 399,900 to lock in access for four years.

Airline says hikes will 'cover cost increases passed on from suppliers'

"This is the first time the Qantas Club membership fees have increased in seven years and will help cover cost increases passed on from a range of suppliers over that time," a Qantas spokesperson confirmed to Simple Flying. "This follows a reduction in the membership fees for several years during the pandemic."

The spokesperson said the gains from the increases will go both towards making up for inflation-related costs and keeping existing lounges looking modern by updating features like furniture and décor.

While the price increases also do not apply for those who earned lounge access through frequent flyer status or change what it takes to earn that status, Qantas is also introducing even steeper increases for those renewing a membership or adding additional features such as spouse and partner memberships.

In some cases, the cost of these features will nearly double from what members are paying now.

Read More

Continue Reading

Uncategorized

PR55α-controlled PP2A Inhibits p16 Expression and Blocks Cellular Senescence Induction

“Our results show that PR55α specifically reduces p16 expression […]” Credit: 2024 Palanivel et al. “Our results show that PR55α specifically…

Published

2 hours ago

on

March 19, 2024

By

“Our results show that PR55α specifically reduces p16 expression […]”

Credit: 2024 Palanivel et al.

“Our results show that PR55α specifically reduces p16 expression […]”

BUFFALO, NY- March 19, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 5, entitled, “PR55α-controlled protein phosphatase 2A inhibits p16 expression and blocks cellular senescence induction by γ-irradiation.”

Cellular senescence is a permanent cell cycle arrest that can be triggered by both internal and external genotoxic stressors, such as telomere dysfunction and DNA damage. The execution of senescence is mainly by two pathways, p16/RB and p53/p21, which lead to CDK4/6 inhibition and RB activation to block cell cycle progression. While the regulation of p53/p21 signaling in response to DNA damage and other insults is well-defined, the regulation of the p16/RB pathway in response to various stressors remains poorly understood. 

In this new study, researchers Chitra Palanivel, Lepakshe S. V. Madduri, Ashley L. Hein, Christopher B. Jenkins, Brendan T. Graff, Alison L. Camero, Sumin Zhou, Charles A. Enke, Michel M. Ouellette, and Ying Yan from the University of Nebraska Medical Center report a novel function of PR55α, a regulatory subunit of PP2A Ser/Thr phosphatase, as a potent inhibitor of p16 expression and senescence induction by ionizing radiation (IR), such as γ-rays. 

“During natural aging, there is a gradual accumulation of p16-expressing senescent cells in tissues [76]. To investigate the significance of PR55α in this up-regulation of p16, we compared levels of the p16 and PR55α proteins in a panel of normal tissue specimens derived from young (≤43 y/o) and old (≥68 y/o) donors.”

The results show that ectopic PR55α expression in normal pancreatic cells inhibits p16 transcription, increases RB phosphorylation, and blocks IR-induced senescence. Conversely, PR55α-knockdown by shRNA in pancreatic cancer cells elevates p16 transcription, reduces RB phosphorylation, and triggers senescence induction after IR. Furthermore, this PR55α function in the regulation of p16 and senescence is p53-independent because it was unaffected by the mutational status of p53. Moreover, PR55α only affects p16 expression but not p14 (ARF) expression, which is also transcribed from the same CDKN2A locus but from an alternative promoter. In normal human tissues, levels of p16 and PR55α proteins were inversely correlated and mutually exclusive. 

“Collectively, these results describe a novel function of PR55α/PP2A in blocking p16/RB signaling and IR-induced cellular senescence.”
 

Read the full paper: DOI: https://doi.org/10.18632/aging.205619 

Corresponding Authors: Michel M. Ouellette, Ying Yan

Corresponding Emails: mouellet@unmc.edu, yyan@unmc.edu

Keywords: p16, p14, CDKN2A locus, p53, RB, PR55α, PP2A, γ-irradiation

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###

Journal

Aging-US

DOI

10.18632/aging.205619

Method of Research

Experimental study

Subject of Research

Cells

Article Title

PR55α-controlled protein phosphatase 2A inhibits p16 expression and blocks cellular senescence induction by γ-irradiation

Article Publication Date

4-Mar-2024

Read More

Continue Reading

Uncategorized

Wall Street Bonuses Fall For Second Year To 2019 Lows Amid Capital Markets Freeze

Wall Street Bonuses Fall For Second Year To 2019 Lows Amid Capital Markets Freeze

Wall Street bonuses have declined for two consecutive years,…

Published

3 hours ago

on

March 19, 2024

By

Wall Street Bonuses Fall For Second Year To 2019 Lows Amid Capital Markets Freeze

Wall Street bonuses have declined for two consecutive years, falling to levels last seen in 2019, according to the latest yearly figures released by New York State Comptroller Thomas P. DiNapoli. This trend is occurring amidst a multi-year downturn in capital markets due to the Federal Reserve's interest rate hiking cycle.

According to the report, the average Wall Street cash bonus fell 2% to $176,500 in 2023, the lowest level since 2019. The drop was far less than the 25% plunge in 2022. Last year's bonus pool was $33.8 billion, unchanged from the previous year but far less than the $42.7 billion during the stock market mania in 2021. 

Source: Bloomberg 

"Wall Street's average cash bonuses dipped slightly from last year, with continued market volatility and more people joining the securities workforce," DiNapoli said in a news release on Tuesday. 

He continued: "While these bonuses affect income tax revenues for the state and city, both budgeted for larger declines so the impact on projected revenues should be limited." 

"The securities industry's continued strength should not overshadow the broader economic picture in New York, where we need all sectors to enjoy full recovery from the pandemic," he added.

Despite the slump, the report said Wall Street's profits rose 1.8% last year, "but firms have taken a more cautious approach to compensation, and more employees have joined the securities industry, which accounts for the slight decline in the average bonus." 

The report showed the industry employed 198,500 people in 2023, up from 191,600 the prior year. This expansion occurred during a period when US banks laid off 23,000 jobs. 

Given that swaps traders and economists at Goldman Sachs Group are forecasting fewer Fed interest-rate cuts this year, a higher-for-longer rates environment will continue to discourage capital-market activity. 

There's about a 50% chance of a June cut. Over the last several months, the Fed's interest-rate target implied by overnight index swaps and SOFR futures went from 700bps of cuts to currently 292bps of cuts for the full year. 

Any delay in the easing cycle will only mean another year of depressed bonuses for Wall Street. 

Tyler Durden Tue, 03/19/2024 - 10:00

Read More

Continue Reading

Trending